Analyst Scoreboard: 5 Ratings For Twist Bioscience

In the preceding three months, 5 analysts have released ratings for Twist Bioscience TWST, presenting a wide array of perspectives from bullish to bearish.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

Analysts have recently evaluated Twist Bioscience and provided 12-month price targets. The average target is $43.6, accompanied by a high estimate of $45.00 and a low estimate of $40.00. Witnessing a positive shift, the current average has risen by 40.65% from the previous average price target of $31.00.

Exploring Analyst Ratings: An In-Depth Overview

The standing of Twist Bioscience among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Twist Bioscience. This insight gives a snapshot of analysts' perspectives on the current state of the company.
• Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Twist Bioscience compared to the broader market.
• Price Targets: Understanding forecasts, analysts offer estimates for Twist Bioscience's future value. Examining the current and prior targets provides insight into analysts' changing expectations.

For valuable insights into Twist Bioscience's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on Twist Bioscience analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

All You Need to Know About Twist Bioscience

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of its revenue from the United States.

Financial Milestones: Twist Bioscience's Journey

Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.

Revenue Growth: Over the 3 months period, Twist Bioscience showcased positive performance, achieving a revenue growth rate of 31.81% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Twist Bioscience's net margin excels beyond industry benchmarks, reaching -60.15%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Twist Bioscience's ROE stands out, surpassing industry averages. With an impressive ROE of -7.09%, the company demonstrates effective use of equity capital and strong financial performance.

Return on Assets (ROA): Twist Bioscience's ROA stands out, surpassing industry averages. With an impressive ROA of -5.7%, the company demonstrates effective utilization of assets and strong financial performance.

Debt Management: With a below-average debt-to-equity ratio of 0.16, Twist Bioscience adopts a prudent financial strategy, indicating a balanced approach to debt management.

The Core of Analyst Ratings: What Every Investor Should Know

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.

This article was generated by Benzinga's automated content engine and reviewed by an editor.